Catalytic nucleic acids: From lab to applications

Pharmacological Reviews

Volumn 52, Issue 3, 2000, Pages 325-347

  Sun, Lun Quan ^a   Cairns, M J ^a   Saravolac, E G ^a   Baker, A ^a   Gerlach, W L ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME; DNA; ENZYME; NUCLEIC ACID; OLIGONUCLEOTIDE; RIBONUCLEASE P; RIBOZYME; RNA; UNCLASSIFIED DRUG;

ARTICLE; CATALYST; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; GENE TARGETING; GENE THERAPY; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOMODULATION; INTRON; NONHUMAN; PRIORITY JOURNAL; RNA CLEAVAGE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BASE SEQUENCE; DNA; HUMANS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; RNA, CATALYTIC;

EID: 0033832018     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (192)

1. Mixed-backbone oligonucleotides as second generation anti-sense oligonucleotides: In vitro and in vivo studies
2. Human gene therapy
3. Direct evolution of an RNA enzyme
4. Secondary structure of the self-cleaving RNA of hepatitis delta virus: Application to catalytic RNA design
5. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance
6. Cationic porphyrins: Novel delivery vehicles for antisense oligodeoxynucleotides
7. Antisense oligonucleotides: Is the glass half full or half empty?
8. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
9. Inhibition of human immunodeficiency virus expression by sense transcripts encoding the retroviral leader RNA
10. Liver uptake of phosphodiester oligonucleotides is mediated by scavenger receptors
11. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial liver cells
12. T lymphocyte-directed gene transfer for ADA-SCID: Initial trial results after 4 years
13. Characterization and modulation of immune stimulation by modified oligonucleotides
14. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake
15. Designing ribozymes for the inhibition of gene expression
16. Efficient cleavage and a common structural motif for the ribozymes of the human hepatitis delta agent
17. DNA Enzymes
18. A DNA enzyme that cleaves RNA
19. +)-dependent RNA phosphoesterase activity
20. Inhibition of translation of hepatitis C virus RNA by 2'-modified antisense oligonucleotides
21. The influence of arm length asymmetry and base substitution on the activity of the '10-23' DNA enzyme
22. Target site selection for an RNA-cleaving catalytic DNA
23. Nucleic acid mutation analysis using catalytic DNA
24. Cleaving DNA with DNA
25. Self-splicing of group I introns
26. RNA catalysis by a group I ribozyme. Developing a model for transition state stablization
27. In vitro splicing of the ribosomal RNA precoursor of Tetrahymena: Involvement of guanosine nucleotide in the excision of the intervening sequence
28. A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant siblings
29. Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro
30. Progress in antisense oligonucleotide therapeutics
31. An overview of progress in antisense therapeutics
32. A DNA metalloenzyme with DNA ligase activity
33. Role of divalent metal ions in the hammerhead RNA cleavage reaction
34. Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion
35. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery
36. Pharmacokinetics of a synthetic chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections
37. Substrate sequence effects on 'hammerhead' RNA catalytic efficiency
38. Cellular uptake properties of a 2'-amino/2'O-methyl-modified chimeric hammerhead ribozyme target to the epidermal growth factor mRNA
39. Crystal structure of a hepatitis delta virus ribozyme
40. Nuclease-resistant ribozyme decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint
41. Ribonuclease P unity and diversity in a tRNA processing ribozyme
42. Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity
43. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
44. Ion dependence of the Bacillus subtilis RNase P reaction
45. Nucleic acid therapeutics: State of the art and future prospects
46. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)
47. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the coreceptor function by DNA-enzyme
48. Antisense raf oligodeoxynucleotide is a radiosensitizer in vivo
49. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
50. In vitro genetic analysis of the Tetrahymena self-splicing intron
51. Selection of a ribozyme that functions as a superior template in a self-copying reaction
52. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme
53. Phenotypic conversion of drug-resistant bacteria to drug sensitivity
54. Solution structures of DNA-RNA hybrids with purine-rich and pyrimidine-rich strands: Comparison with homologous DNA and RNA duplexes
55. RNA catalytic properties of the minimum (-) sTRSV sequence
56. Simple RNA enzymes with new and highly specific endoribonuclease activities
57. High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleotides and phosphorothioates
58. Hammerhead ribozyme-mediated cleavage of the long terminal repeat of human immunodeficiency virus type 1
59. Unexpected anisotropy in substrate cleavage rates by asymmetric hammerhead ribozymes
60. In vitro activity of minimised hammerhead ribozymes
61. Inhibition of coagulation by a phosphorothioate oligonucleotide
62. Correlation of toxicology and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
63. DNA cleavage catalysed by the ribozyme from Tetrahymena
64. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction
65. Specificity of hammerhead ribozyme cleavage
66. An antisense oligonucleotide primer
67. Cationic lipids, phosphatidyleth-anolamine and the intracellular delivery of polymeric, nucleic acid-based drugs
68. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H
69. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA
70. Optimizing the cell efficiency of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the protooncogene c-myb
71. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells
72. Evaluating and enhancing ribozyme reaction efficiency in mammalian cells
73. Nucleic acid enzymes: Playing with a fuller deck
74. Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides
75. Substrate recognition by RNase P and by the catalytic M1 RNA: Identification of possible contact points in pre-tRNAs
76. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity
77. Targeted gene repair
78. Enzymatic approaches to probing of RNA secondary the tertiary structure
79. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule
80. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: Diasteroselectivity of plasma 3'exonuclease
81. CpG motifs in bacterial DNA trigger direct B-cell activation
82. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA
83. The molecular biology of hepatitis delta virus
84. Involvement of aminoacyl-tRNA synthetases and other proteins in group I and group II intron splicing
85. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors
86. Quantitation of phosphorothioate oligonucleotides in human plasma
87. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
88. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit
89. Evolution in vitro of an RNA enzyme with altered metal dependence
90. Phosphorylating DNA with DNA
91. Deoxyribozymes: New players in the ancient game of biocatalysis
92. Oligonucleotide delivery: A cellular prospective
93. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library
94. Fate of cationic liposomes and their complex with oligonucleotide in vivo
95. Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli
96. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat RNA
97. Extending the cleavage rules for the hammerhead ribozyme: Mutating adenosine15.1 to inosine15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17
98. Replication of hepatitis delta virus RNA: Effect of mutations of the autocatalytic cleavage sites
99. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipid before entering the nucleus
100. Minimal sequence requirements for ribozyme activity
101. Modelling of the three-dimensional architecture of group I catalytic introns based on comparative sequence analysis
102. Human gene therapy comes of age
103. Current concepts in antisense drug design
104. A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the Tetrahymena ribozyme
105. Evaluation of the renal effects of antisense phosphorothioate oligodeoxynucleotide in monkeys
106. Synthetic oligonucleotides: The development of antisense therapeutics
107. The structural basis of hammerhead ribozyme self-cleavage
108. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation
109. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme
110. Antisense effect of oligodeoxynucleotides with inverted terminal inter-nucleotidic linkages: A minimal modification protecting against nucleolytic degradation
111. Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity
112. Nuclease resistant ribozymes with high catalytic activity
113. Secondary structure of mouse and rabbit alpha- and beta-globin mRNA: Differential accessibility of alpha and beta initiator AUG codons towards nucleases
114. Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity
115. Extended target-site specificity for a hammerhead ribozyme
116. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis delta virus RNA sequence
117. Assessment of disparate structural features in three models of the hepatitis delta virus ribozyme
118. Experimental evidence for the secondary structure of the hepatitis delta virus ribozyme
119. Antisense therapeutics
120. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP69846A) after intravenous and subcutaneous administration
121. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes
122. Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P
123. Intracellular metabolism of 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis
124. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy
125. A circular trans-acting hepatitis delta virus ribozyme
126. Sequence specific thermodynamic and structural properties for DNA. Rna duplexes
127. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion in mice
128. Role of the protein moiety of ribonuclease P, a ribonucleoprotein enzyme
129. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA
130. A phase I trial of autologous CD34+ haematopoietic progenitor cells transduced with an anti-HIV-1 ribozyme
131. Self-cleavage of hepatitis delta virus genomic strand RNA is enhanced under partially denaturing conditions
132. Ribozymes
133. Delta ribozyme has the ability to cleave in trans an mRNA
134. Reduction of fibronectin expression by intravitreal adminisitration of antisense oligonucleotides
135. Thiophosphate interference experiments locate phosphates important for the hammerhead RNA self-cleavage reaction
136. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME(TM)) in the mouse
137. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury
138. A general purpose RNA-cleaving DNA enzyme
139. Mechanism and utility of an RNA-cleaving DNA enzyme
140. Ribozymes as potential anti-HIV-1 therapeutic agents
141. Disposition of oligonucleotides in isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake
142. Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites
143. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents
144. Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme
145. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications
146. Pharmacokinetics and tolerablility of intravenous trecovirsen (Gem91), an antisense phosphorothioate oligonucleotide in HIV-positive subjects
147. + ions
148. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo
149. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates
150. A minimised hammerhead ribozyme with activity against interleukin-2 in human cells
151. A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth
152. How to design an antisense oligonucleotide experiment: A consensus approach
153. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine
154. Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes
155. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing
156. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
157. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme
158. Anti-HIV ribozymes
159. Resistance to HIV-1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense or polyTAR constructs
160. Ribozyme-mediated suppression of moloney murine leukemia virus and human immunodeficiency virus type 1 replication in permissive cell lines
161. Ribozymes
162. Ribozymes: The characteristics and properties of catalytic RNAs
163. Antitumor activity and pharmacokinetics of a mixed-backbone antisense olignucleotide targeted to the RIα subunit protein kinase A after oral administration
164. Preclinical characterization of an anti-tat ribozyme for therapeutic application
165. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome
166. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
167. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme
168. mRNA splicing and autocatalytic introns: Distant cousins or the products of chemical determinism?
169. Expression of ribozymes in gene transfer systems to modulate target RNA levels
170. Targeted cleavage of RNA molecules by human RNase P using minimized external guide sequences
171. Function of specific 2'-hydroxyl groups of guanosines in a hammerhead ribozyme probed by 2' modifications
172. Synthesis, deprotection, analysis and purification of RNA and ribozymes
173. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients
174. Mutagenesis analysis of a hepatitis delta virus genomic ribozyme
175. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes)
176. Design, synthesis and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers
177. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain
178. Sequence-specific cleavage of Huntington mRNA by catalytic DNA
179. Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes. The most effective ribozymes are not predicted by substrate selection rules
180. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-RAS encapsulated in stealth liposomes
181. Substrate recognition by human RNase P: Identification of small, model substrates for the enzyme
182. Targeted cleavage of mRNA by human RNase P
183. Mechanism of oligonucleotide release from cationic liposomes
184. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration
185. In vivo stability, disposition and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats
186. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme
187. Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice
188. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes